摘要
骨髓增生异常综合征(MDS)是一组高度异质性获得性造血干/祖细胞克隆性疾病,以骨髓病态造血和向急性白血病转化的高风险为特点。近年来,MDS的治疗取得了一些进展,而不再局限于原先的支持治疗。异基因造血干细胞移植仍是目前唯一能使MDS长期缓解甚至治愈的方法,在药物治疗方面除了FDA批准应用的来那度胺、地西他滨和阿扎胞苷外,一些新兴药物如RAP-536,英夫利昔单克隆抗体,组蛋白脱乙酰基酶抑制剂以及联合疗法等亦被用于MDS的治疗。本文主要将近几年来关于MDS治疗方面的一些进展加以总结,以期对该病的治疗现状有进一步的了解。
Myelodysplastic syndrome （MDS） is a group of highly heterogeneous clonal disorders of myeloid hematopoietic stem cells, frequently characterized by bone marrow dysplasia and increased risks of transformation into acute myeloid leukemia. In recent years, several advances have been acquired in the treatment of MDS. Allogeneic hematopoietic stem cell transplantation is still the only way to make MDS to be long-term remission and even cure. And as for the use of drug, besides lenalidomide, decitabine and azacitidine approved by FDA, other medicines such as RAP- 536, HDAC inhibitor, infliximab and combination therapy have also been used. This article focuses attention on the recent advances of the MDS treatment in hope of better understanding the present therapeutic status for MDS.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2012年第6期1522-1525,共4页
Journal of Experimental Hematology
基金
江苏省医学重点学科资助项目(编号2011-12)
